ABT 834
Alternative Names: ABT-834Latest Information Update: 23 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 27 Aug 2007 Discontinued - Phase-I for Cognition disorders in USA (unspecified route)
- 30 Jun 2003 Phase-I clinical trials in Cognition disorders in USA (unspecified route)